

Bitte beachten Sie: Dieses Dokument wurde automatisch erstellt und ist kein Ersatz für das Originaldokument des Herstellers.

Product Datasheet

Goat IgG anti-Human IgG (F(ab)2)-FITC, MinX none DNA-SEC-183014

Artikelname	Goat IgG anti-Human IgG (F(ab)2)-FITC, MinX none
Artikelnummer	DNA-SEC-183014
Hersteller Artikelnummer	SEC-183014
Alternativnummer	DNA-SEC-183014
Hersteller	dianova
Wirt	Goat
Kategorie	Antikörper
Applikation	FLISA,FACS,IF
Spezies Reaktivität	Human
Immunogen	Human IgG F(ab)2 fragment
Konjugation	FITC
Format	IgG
Spezifität	IgG (F(ab')2)
Minimale Kreuzreaktivität (MinX)	no cross-adsorbtion
Produktbeschreibung	Anti-Human IgG F(ab)2 Fluorescein Antibody generated in goat recognizes the dimeric Fab portion of the human IgG molecule. Human IgG F(ab)2 is a proteolytic fragment of immunoglobulin G (IgG) obtained by limited digestion with the enzyme pepsin under...
Klonalität	Polyclonal

Konzentration	2.0 mg/mL
Isotyp	Ig
Puffer	0.02 M Potassium Phosphate, 0.15 M Sodium Chloride, pH 7.2
Reinheit	This product was prepared from monospecific antiserum by immunoaffinity chromatography using Human IgG coupled to agarose beads followed by solid phase adsorption(s) to remove any unwanted reactivities. Assay by immunoelectrophoresis resulted in a single precipitin arc against anti-Fluorescein, anti-Goat Serum, Human IgG, Human IgG F(ab') ₂ and Human Serum. No reaction was observed against Human IgG F(c).
Formulierung	Lyophilized
Formel	20 mM K ₃ PO ₄ , 150 mM NaCl, pH 7.2, lyophilisate, 0.01% NaN ₃
Target-Kategorie	Human
Antibody Type	Secondary Antibody
Application Verdünnung	FLISA Dilution: 1:10,000 - 1:50,000, Flow Cytometry Dilution: 1:500 - 1:2,500, Fluorochrome Protein Value: 3.0, IF Microscopy Dilution: 1:1,000 - 1:5,000
Anwendungsbeschreibung	Anti-Human IgG F(ab') ₂ Fluorescein Antibody is designed for immunofluorescence microscopy, fluorescence based plate assays (FLISA) and fluorescent western blotting. This product is also suitable for multiplex analysis, including multicolor imaging, utilizing various commercial platforms.